Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

ACC 2024 Congress

Catch up on all the top stories and latest evidence in cardiology research with our ACC 2024 Congress hub page.
ADVANCED SEARCH
Log in
Top
Journal of Gastroenterology
Published in: Journal of Gastroenterology 1/2013

Open Access 01-01-2013 | Review

Evidence-based clinical practice guidelines for Crohn’s disease, integrated with formal consensus of experts in Japan

Authors: Fumiaki Ueno, Toshiyuki Matsui, Takayuki Matsumoto, Katsuyoshi Matsuoka, Mamoru Watanabe, Toshifumi Hibi, On Behalf of the Guidelines Project Group of the Research Group of Intractable Inflammatory Bowel Disease subsidized by the Ministry of Health, Labour and Welfare of Japan and the Guidelines Committee of the Japanese Society of Gastroenterology

Published in: Journal of Gastroenterology | Issue 1/2013

Login to get access

Abstract

Crohn’s disease is a disorder of unknown etiology and complicated pathogenesis. A substantial amount of evidence has accumulated recently and has been applied to clinical practice. The present guidelines were developed based on recent evidence and the formal consensus of experts relevant to this disease. Here we provide an overview of these guidelines, as follows.
  • Target disease: Crohn’s disease
  • Users: Clinical practitioners in internal medicine, surgery, gastroenterology, and general practice
  • Purpose: To provide appropriate clinical indicators to practitioners
  • Scope of clinical indicators: Concept of Crohn’s disease, epidemiology, classifications, diagnosis, treatment, follow up, and special situations
  • Intervention: Diagnosis (interview, physical examination, clinical laboratory tests, imaging, and pathology) and treatment (lifestyle guidance, drug therapy, nutritional therapy, surgery, etc.)
  • Outcome assessment: Attenuation of symptoms, induction and maintenance of remission, imaging findings, quality of life (QOL), prevention of complications and harm of therapy
  • Methods for developing these guidelines: Described in the text
  • Basis of recommendations: Integration of evidence level and consensus of experts
  • Cost-benefit analysis: Not implemented
  • Evaluation of effectiveness: Yet to be confirmed
  • Status of guidelines: Updated version of the first Guidelines published in 2010
  • Publication sources: Printed publication available and electronic information in preparation
  • Patient information: Not available
  • Date of publication: October 2011
These guidelines were intended primarily to be used by practitioners in Japan, and the goal of these guidelines is to improve the outcomes of patients with Crohn’s disease.
Literature
1.
Shiffman RN, Shekelle P, Overhage JM, Slutsky J, Grimshaw J, Deshpande AM. Standardized reporting of clinical practice guidelines: a proposal from the Conference on Guideline Standardization. Ann Intern Med. 2003;139:493–8.PubMed
2.
Jewell DP. Oxford textbook of medicine. 4th ed. Oxford University Press, Oxford; 2005.
3.
Morita N, Toki S, Hirohashi T, Minoda T, Ogawa K, Kono S, et al. Incidence and prevalence of inflammatory bowel disease in Japan: nationwide epidemiological survey during the year 1991. J Gastroenterol. 1995;30:1–4.PubMedCrossRef
4.
Yao T, Matsui T, Hiwatashi N. Crohn’s disease in Japan: diagnostic criteria and epidemiology. Dis Colon Rectum. 2000;43:S85–93.PubMedCrossRef
5.
Ohta A, Nagai M, Nishina M, Shibazaki S, Ishijima H, Izumida M. Age at the onset of intractable disease: based on a clinical database for patients receiving financial aid for treatment. Nihon Koshu Eisei Zasshi. 2007;54:3–14 (in Japanese).
6.
Loftus EV Jr. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology. 2004;126:1504–17.PubMedCrossRef
7.
Loftus EV Jr, Schoenfeld P, Sandborn WJ. The epidemiology and natural history of Crohn’s disease in population-based patient cohorts from North America: a systematic review. Aliment Pharmacol Ther. 2002;16:51–60.PubMedCrossRef
8.
Isaacs KL, Lewis JD, Sandborn WJ, Sands BE, Targan SR. State of the art: IBD therapy and clinical trials in IBD. Inflamm Bowel Dis. 2005;11:S3–12.PubMedCrossRef
9.
Hibi T, Ogata H. Novel pathophysiological concepts of inflammatory bowel disease. J Gastroenterol. 2006;41:10–6.PubMedCrossRef
10.
11.
Orholm M, Munkholm P, Langholz E, Nielsen OH, Sorensen TI, Binder V. Familial occurrence of inflammatory bowel disease. N Engl J Med. 1991;324:84–8.PubMedCrossRef
12.
Peeters M, Nevens H, Baert F, Hiele M, de Meyer AM, Vlietinck R, et al. Familial aggregation in Crohn’s disease: increased age-adjusted risk and concordance in clinical characteristics. Gastroenterology. 1996;111:597–603.PubMedCrossRef
13.
Jarnerot G, Jarnmark I, Nilsson K. Consumption of refined sugar by patients with Crohn’s disease, ulcerative colitis, or irritable bowel syndrome. Scand J Gastroenterol. 1983;18:999–1002.PubMedCrossRef
14.
Tragnone A, Valpiani D, Miglio F, Elmi G, Bazzocchi G, Pipitone E, et al. Dietary habits as risk factors for inflammatory bowel disease. Eur J Gastroenterol Hepatol. 1995;7:47–51.PubMed
15.
Sakamoto N, Kono S, Wakai K, Fukuda Y, Satomi M, Shimoyama T, et al. Dietary risk factors for inflammatory bowel disease: a multicenter case–control study in Japan. Inflamm Bowel Dis. 2005;11:154–63.PubMedCrossRef
16.
Ryan WR, Allan RN, Yamamoto T, Keighley MR. Crohn’s disease patients who quit smoking have a reduced risk of reoperation for recurrence. Am J Surg. 2004;187:219–25.PubMedCrossRef
17.
Parsi MA, Achkar JP, Richardson S, Katz J, Hammel JP, Lashner BA, et al. Predictors of response to infliximab in patients with Crohn’s disease. Gastroenterology. 2002;123:707–13.PubMedCrossRef
18.
Felder JB, Korelitz BI, Rajapakse R, Schwarz S, Horatagis AP, Gleim G. Effects of nonsteroidal antiinflammatory drugs on inflammatory bowel disease: a case–control study. Am J Gastroenterol. 2000;95:1949–54.PubMedCrossRef
19.
Boyko EJ, Theis MK, Vaughan TL, Nicol-Blades B. Increased risk of inflammatory bowel disease associated with oral contraceptive use. Am J Epidemiol. 1994;140:268–78.PubMed
20.
Gasche C, Scholmerich J, Brynskov J, D’Haens G, Hanauer SB, Irvine EJ, et al. A simple classification of Crohn’s disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998. Inflamm Bowel Dis. 2000;6:8–15.PubMedCrossRef
21.
Carter MJ, Lobo AJ, Travis SP. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2004;53:V1–16.PubMedCrossRef
22.
Ueno F, Ide H, Yanagawa T. Factors that affect the status of employment of patients with Crohn’s disease: a study of subjective and objective indexes. Annual reports of research group on QOL in specified disease cases supported by the Ministry of Health, Labour, and Welfare of Japan, Tokyo, Japan, 1998. p. 125–36 (in Japanese).
23.
Takebayashi T, Nishiwaki Y, Asakura K, Kitabora T, Inoue N. An epidemiological study on the incidence, prevalence, and prognosis of intractable inflammatory bowel disorders. Annual reports of the research group of intractable inflammatory bowel disease subsidized by the Ministry of Health, Labour, and Welfare of Japan, Tokyo, Japan, 2007. p. 79–83 (in Japanese).
24.
von Roon AC, Reese G, Teare J, Constantinides V, Darzi AW, Tekkis PP. The risk of cancer in patients with Crohn’s disease. Dis Colon Rectum. 2007;50:839–55.CrossRef
25.
Matsui T, Yano Y, Hirai F. Crohn’s disease and intestinal cancer. Nihon Shokakibyo Gakkai Zasshi. 2006;103:797–804 (in Japanese).
26.
Yano Y, Matsui T, Uno H, Hirai F, Futami K, Iwashita A. Risks and clinical features of colorectal cancer complicating Crohn’s disease in Japanese patients. J Gastroenterol Hepatol. 2008;23:1683–8.PubMedCrossRef
27.
Wolters FL, Russel MG, Stockbrugger RW. Systematic review: has disease outcome in Crohn’s disease changed during the last four decades? Aliment Pharmacol Ther. 2004;20:483–96.PubMedCrossRef
28.
Oriuchi T, Hiwatashi N, Kinouchi Y, Takahashi S, Takagi S, Negoro K, et al. Clinical course and longterm prognosis of Japanese patients with Crohn’s disease: predictive factors, rates of operation, and mortality. J Gastroenterol. 2003;38:942–53.PubMedCrossRef
29.
Uno H, Yao T, Matsui T, Sakurai T, Iida M, Matsumoto T, et al. Mortality and cause of death in Japanese patients with Crohn’s disease. Dis Colon Rectum. 2003;46:S15–21.PubMed
30.
Forbes A. Clinical presentation and diagnosis of Crohn’s disease. In: Satsangi J, Southerland L, editors. Inflammatory bowel disease. Philadelphia: Churchill Livingstone; 2003.
31.
Beaugerie L, Seksik P, Nion-Larmurier I, Gendre JP, Cosnes J. Predictors of Crohn’s disease. Gastroenterology. 2006;130:650–6.PubMedCrossRef
32.
Orchard TR, Thiyagaraja S, Welsh KI, Wordsworth BP, Hill Gaston JS, Jewell DP. Clinical phenotype is related to HLA genotype in the peripheral arthropathies of inflammatory bowel disease. Gastroenterology. 2000;118:274–8.PubMedCrossRef
33.
Munkholm P, Langholz E, Nielsen OH, Kreiner S, Binder V. Incidence and prevalence of Crohn’s disease in the county of Copenhagen, 1962–87: a sixfold increase in incidence. Scand J Gastroenterol. 1992;27:609–14.PubMedCrossRef
34.
Bernstein CN, Blanchard JF, Rawsthorne P, Yu N. The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study. Am J Gastroenterol. 2001;96:1116–22.PubMedCrossRef
35.
Travis S, Innes N, Davies MG, Daneshmend T, Hughes S. Sweet’s syndrome: an unusual cutaneous feature of Crohn’s disease or ulcerative colitis. The South West Gastroenterology Group. Eur J Gastroenterol Hepatol. 1997;9:715–20.PubMedCrossRef
36.
Sandborn WJ, Fazio VW, Feagan BG, Hanauer SB. AGA technical review on perianal Crohn’s disease. Gastroenterology. 2003;125:1508–30.PubMedCrossRef
37.
Hughes LE. Surgical pathology and management of anorectal Crohn’s disease. J R Soc Med. 1978;71:644–51.PubMed
38.
Futami K. Atlas of findings by visual observation of lesions in the anus of Crohn’s disease. Annual reports of the research group of intractable inflammatory bowel disease subsidized by the Ministry of Health, Labour, and Welfare of Japan, Tokyo, Japan, 2006. Suppl. (in Japanese).
39.
Matsui T, Hirai F, Hisabe T. Proposed diagnostic criteria for Crohn’s disease. Annual reports of the research group of intractable inflammatory bowel disease subsidized by the Ministry of Health, Labour, and Welfare of Japan, Tokyo, Japan, 2011. p. 52–4 (in Japanese).
40.
Hommes DW, van Deventer SJ. Endoscopy in inflammatory bowel diseases. Gastroenterology. 2004;126:1561–73.PubMedCrossRef
41.
Witte AM, Veenendaal RA, Van Hogezand RA, Verspaget HW, Lamers CB. Crohn’s disease of the upper gastrointestinal tract: the value of endoscopic examination. Scand J Gastroenterol Suppl. 1998;225:100–5.PubMed
42.
Best WR, Becktel JM, Singleton JW, Kern F Jr. Development of a Crohn’s disease activity index. National Cooperative Crohn’s Disease Study. Gastroenterology. 1976;70:439–44.PubMed
43.
Mary JY, Modigliani R. Development and validation of an endoscopic index of the severity for Crohn’s disease: a prospective multicentre study. Groupe d’Etudes Therapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut. 1989;30:983–9.PubMedCrossRef
44.
Denis MA, Reenaers C, Fontaine F, Belaiche J, Louis E. Assessment of endoscopic activity index and biological inflammatory markers in clinically active Crohn’s disease with normal C-reactive protein serum level. Inflamm Bowel Dis. 2007;13:1100–5.PubMedCrossRef
45.
IBD Working Group of the European Society for Paediatric Gastroenterology Hepatology, and Nutrition. Inflammatory bowel disease in children and adolescents: recommendations for diagnosis—the Porto criteria. J Pediatr Gastroenterol Nutr. 2005;41:1–7.CrossRef
46.
Pera A, Bellando P, Caldera D, Ponti V, Astegiano M, Barletti C, et al. Colonoscopy in inflammatory bowel disease. Diagnostic accuracy and proposal of an endoscopic score. Gastroenterology. 1987;92:181–5.PubMed
47.
Saibeni S, Rondonotti E, Iozzelli A, Spina L, Tontini GE, Cavallaro F, et al. Imaging of the small bowel in Crohn’s disease: a review of old and new techniques. World J Gastroenterol. 2007;13:3279–87.PubMed
48.
Taruishi M, Saitoh Y, Watari J, Ashida T, Ayabe T, Takemura K, et al. Balloon-occluded endoscopic retrograde ileography. Radiology. 2000;214:908–11.PubMed
49.
Iida M, Aoyagi K, Atsushi K. Crohn’s disease—X-ray examination of the small intestine. Stomach Intestine. 1997;32:341–50 (in Japanese).
50.
Tominaga M. Clinical features of Crohn’s disease: relationship of disease type and severity to clinical findings at the time of diagnosis in 166 cases. Fukuoka Igaku Zasshi. 1992;83:6–20 (in Japanese).
51.
Horsthuis K, Stokkers PC, Stoker J. Detection of inflammatory bowel disease: diagnostic performance of cross-sectional imaging modalities. Abdom Imaging. 2008;33:407–16.PubMedCrossRef
52.
Nikolaus S, Schreiber S. Diagnostics of inflammatory bowel disease. Gastroenterology. 2007;133:1670–89.PubMedCrossRef
53.
Ota Y, Matsui T, Ono H, Uno H, Matake H, Tsuda S, et al. Value of virtual computed tomographic colonography for Crohn’s colitis: comparison with endoscopy and barium enema. Abdom Imaging. 2003;28:778–83.PubMedCrossRef
54.
Meucci G, Bortoli A, Riccioli FA, Girelli CM, Radaelli F, Rivolta R, et al. Frequency and clinical evolution of indeterminate colitis: a retrospective multi-centre study in northern Italy. GSMII (Gruppo di Studio per le Malattie Infiammatorie Intestinali). Eur J Gastroenterol Hepatol. 1999;11:909–13.PubMedCrossRef
55.
Matsui T, Yao T, Sakurai T, Yao K, Hirai F, Matake H, et al. Clinical features and pattern of indeterminate colitis: Crohn’s disease with ulcerative colitis-like clinical presentation. J Gastroenterol. 2003;38:647–55.PubMedCrossRef
56.
Hanauer SB, Sandborn W. Management of Crohn’s disease in adults. Am J Gastroenterol. 2001;96:635–43.PubMedCrossRef
57.
Travis SP, Stange EF, Lemann M, Oresland T, Chowers Y, Forbes A, et al. European evidence based consensus on the diagnosis and management of Crohn’s disease: current management. Gut. 2006;55:i16–35.PubMedCrossRef
58.
Iida M. A study of drug therapies for Crohn’s disease: proposed revision of the clinical practice guidelines for Crohn’s disease. Annual reports of the research group of intractable inflammatory bowel disease subsidized by the Ministry of Health, Labour, and Welfare of Japan, Tokyo, Japan, 2007. p. 27 (in Japanese).
59.
Farrell R, Peppercorn MA. Medical management of Crohn’s disease in adults. In: Basow DS, editor. UpToDate. Waltham; 2007.
60.
Hiwatashi N. Crohn’s disease Q&A. Annual reports of the research group of intractable inflammatory bowel disease subsidized by the Ministry of Health, Labour, and Welfare of Japan, Tokyo, Japan, 1999. p. 43–6 (in Japanese).
61.
Hiwatashi N, Takazoe M. Proposed guidelines for the management of patients with Crohn’s disease. Annual reports of the research group of intractable inflammatory bowel disease subsidized by the Ministry of Health, Labour, and Welfare of Japan, Tokyo, Japan, 2002. p. 220–3 (in Japanese).
62.
Adam D, Adam J, Price H. An analysis of an inflammatory bowel disease practice in an urban community hospital. Can J Gastroenterol. 2000;14:483–8.PubMed
63.
Hirai F, Takatsu N, Ninomiya K, Baba T, Kanemitsu T, Morokuma T, et al. Long-term clinical course and prognosis of patients with Crohn’s disease. Stomach Intestine. 2007;42:1843–58 (in Japanese).
64.
Ng V, Millard W, Lebrun C, Howard J. Exercise and Crohn’s disease: speculations on potential benefits. Can J Gastroenterol. 2006;20:657–60.PubMed
65.
Mahid SS, Minor KS, Soto RE, Hornung CA, Galandiuk S. Smoking and inflammatory bowel disease: a meta-analysis. Mayo Clin Proc. 2006;81:1462–71.PubMedCrossRef
66.
Mahid SS, Minor KS, Stromberg AJ, Galandiuk S. Active and passive smoking in childhood is related to the development of inflammatory bowel disease. Inflamm Bowel Dis. 2007;13:431–8.PubMedCrossRef
67.
Avidan B, Sakhnini E, Lahat A, Lang A, Koler M, Zmora O, et al. Risk factors regarding the need for a second operation in patients with Crohn’s disease. Digestion. 2005;72:248–53.PubMedCrossRef
68.
Cosnes J, Carbonnel F, Carrat F, Beaugerie L, Cattan S, Gendre J. Effects of current and former cigarette smoking on the clinical course of Crohn’s disease. Aliment Pharmacol Ther. 1999;13:1403–11.PubMedCrossRef
69.
Russel MG, Volovics A, Schoon EJ, van Wijlick EH, Logan RF, Shivananda S, et al. Inflammatory bowel disease: is there any relation between smoking status and disease presentation? European Collaborative IBD Study Group. Inflamm Bowel Dis. 1998;4:182–6.PubMedCrossRef
70.
Cosnes J, Beaugerie L, Carbonnel F, Gendre JP. Smoking cessation and the course of Crohn’s disease: an intervention study. Gastroenterology. 2001;120:1093–9.PubMedCrossRef
71.
Vermeire S, Louis E, Carbonez A, Van Assche G, Noman M, Belaiche J, et al. Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn’s disease. Am J Gastroenterol. 2002;97:2357–63.PubMedCrossRef
72.
Benchimol EI, Seow CH, Steinhart AH, Griffiths AM. Traditional corticosteroids for induction of remission in Crohn’s disease. Cochrane Database Syst Rev. 2008;2:CD006792.PubMed
73.
Steinhart AH, Ewe K, Griffiths AM, Modigliani R, Thomsen OO. Corticosteroids for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev. 2003;4:CD000301.PubMed
74.
Seow CH, Benchimol EI, Griffiths AM, Otley AR, Steinhart AH. Budesonide for induction of remission in Crohn’s disease. Cochrane Database Syst Rev. 2008;3:CD000296.PubMed
75.
Hanauer SB, Stromberg U. Oral Pentasa in the treatment of active Crohn’s disease: a meta-analysis of double-blind, placebo-controlled trials. Clin Gastroenterol Hepatol. 2004;2:379–88.PubMedCrossRef
76.
Akobeng AK, Gardener E. Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn’s disease. Cochrane Database Syst Rev. 2005;1:CD003715.PubMed
77.
Steinhart AH, Forbes A, Mills EC, Rodgers-Gray BS, Travis SP. Systematic review: the potential influence of mesalazine formulation on maintenance of remission in Crohn’s disease. Aliment Pharmacol Ther. 2007;25:1389–99.PubMedCrossRef
78.
Sandborn W, Sutherland L, Pearson D, May G, Modigliani R, Prantera C. Azathioprine or 6-mercaptopurine for inducing remission of Crohn’s disease. Cochrane Database Syst Rev. 2000;2:CD000545.PubMed
79.
Pearson DC, May GR, Fick G, Sutherland LR. Azathioprine for maintaining remission of Crohn’s disease. Cochrane Database Syst Rev. 2000;2:CD000067.PubMed
80.
Akobeng AK, Zachos M. Tumor necrosis factor-alpha antibody for induction of remission in Crohn’s disease. Cochrane Database Syst Rev. 2004;1:CD003574.PubMed
81.
Behm BW, Bickston SJ. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev. 2008;1:CD006893.PubMed
82.
Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, et al. Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl J Med. 2004;350:876–85.PubMedCrossRef
83.
Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh D, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology. 2006;130:323–33.PubMedCrossRef
84.
Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology. 2007;132:52–65.PubMedCrossRef
85.
Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Colombel JF, Panaccione R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med. 2007;146:829–38.PubMed
86.
Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Diamond RH, Chen DM, et al. Serious infections and mortality in association with therapies for Crohn’s disease: TREAT registry. Clin Gastroenterol Hepatol. 2006;4:621–30.PubMedCrossRef
87.
Toruner M, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Orenstein R, Sandborn WJ, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology. 2008;134:929–36.PubMedCrossRef
88.
Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001;345:1098–104.PubMedCrossRef
89.
Lichtenstein GR, Olson A, Travers S, Diamond RH, Chen DM, Pritchard ML, et al. Factors associated with the development of intestinal strictures or obstructions in patients with Crohn’s disease. Am J Gastroenterol. 2006;101:1030–8.PubMedCrossRef
90.
Lichtenstein GR, Cohen RD, Feagan BG, Sandborn W, Salzberg BA, Chen DM, et al. Safety of infliximab and other Crohn’s disease therapies—updated TREAT Registry data with over 10,000 patient-years of follow-up. Gastroenterology. 2005;128:A-580.CrossRef
91.
Biancone L, Orlando A, Kohn A, Colombo E, Sostegni R, Angelucci E, et al. Infliximab and newly diagnosed neoplasia in Crohn’s disease: a multicentre matched pair study. Gut. 2006;55:228–33.PubMedCrossRef
92.
Burmester GR, Mease P, Dijkmans BA, Gordon K, Lovell D, Panaccione R, et al. Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases. Ann Rheum Dis. 2009;68:1863–9.PubMedCrossRef
93.
Rahimi R, Nikfar S, Rezaie A, Abdollahi M. A meta-analysis of broad-spectrum antibiotic therapy in patients with active Crohn’s disease. Clin Ther. 2006;28:1983–8.PubMedCrossRef
94.
Prantera C, Kohn A, Mangiarotti R, Andreoli A, Luzi C. Antimycobacterial therapy in Crohn’s disease: results of a controlled, double-blind trial with a multiple antibiotic regimen. Am J Gastroenterol. 1994;89:513–8.PubMed
95.
Prantera C, Zannoni F, Scribano ML, Berto E, Andreoli A, Kohn A, et al. An antibiotic regimen for the treatment of active Crohn’s disease: a randomized, controlled clinical trial of metronidazole plus ciprofloxacin. Am J Gastroenterol. 1996;91:328–32.PubMed
96.
Steinhart AH, Feagan BG, Wong CJ, Vandervoort M, Mikolainis S, Croitoru K, et al. Combined budesonide and antibiotic therapy for active Crohn’s disease: a randomized controlled trial. Gastroenterology. 2002;123:33–40.PubMedCrossRef
97.
Rutgeerts P, Van Assche G, Vermeire S, D’Haens G, Baert F, Noman M, et al. Ornidazole for prophylaxis of postoperative Crohn’s disease recurrence: a randomized, double-blind, placebo-controlled trial. Gastroenterology. 2005;128:856–61.PubMedCrossRef
98.
Fernandez-Banares F, Cabre E, Esteve-Comas M, Gassull MA. How effective is enteral nutrition in inducing clinical remission in active Crohn’s disease? A meta-analysis of the randomized clinical trials. JPEN J Parenter Enteral Nutr. 1995;19:356–64.PubMedCrossRef
99.
Griffiths AM, Ohlsson A, Sherman PM, Sutherland LR. Meta-analysis of enteral nutrition as a primary treatment of active Crohn’s disease. Gastroenterology. 1995;108:1056–67.PubMedCrossRef
100.
Borrelli O, Cordischi L, Cirulli M, Paganelli M, Labalestra V, Uccini S, et al. Polymeric diet alone versus corticosteroids in the treatment of active pediatric Crohn’s disease: a randomized controlled open-label trial. Clin Gastroenterol Hepatol. 2006;4:744–53.PubMedCrossRef
101.
Heuschkel RB, Menache CC, Megerian JT, Baird AE. Enteral nutrition and corticosteroids in the treatment of acute Crohn’s disease in children. J Pediatr Gastroenterol Nutr. 2000;31:8–15.PubMedCrossRef
102.
Okada M, Yao T, Yamamoto T, Takenaka K, Imamura K, Maeda K, et al. Controlled trial comparing an elemental diet with prednisolone in the treatment of active Crohn’s disease. Hepatogastroenterology. 1990;37:72–80.PubMed
103.
Takagi S, Utsunomiya K, Kuriyama S, Yokoyama H, Takahashi S, Iwabuchi M, et al. Effectiveness of an ‘half elemental diet’ as maintenance therapy for Crohn’s disease: a randomized-controlled trial. Aliment Pharmacol Ther. 2006;24:1333–40.PubMedCrossRef
104.
Hirakawa H, Fukuda Y, Tanida N, Hosomi M, Shimoyama T. Home elemental enteral hyperalimentation (HEEH) for the maintenance of remission in patients with Crohn’s disease. Gastroenterol Jpn. 1993;28:379–84.PubMed
105.
Esaki M, Matsumoto T, Hizawa K, Nakamura S, Jo Y, Mibu R, et al. Preventive effect of nutritional therapy against postoperative recurrence of Crohn disease, with reference to findings determined by intra-operative enteroscopy. Scand J Gastroenterol. 2005;40:1431–7.PubMedCrossRef
106.
Sakurai T, Matsui T, Yao T, Takagi Y, Hirai F, Aoyagi K, et al. Short-term efficacy of enteral nutrition in the treatment of active Crohn’s disease: a randomized, controlled trial comparing nutrient formulas. JPEN J Parenter Enteral Nutr. 2002;26:98–103.PubMedCrossRef
107.
Kobayashi K, Katsumata T, Yokoyama K, Takahashi H, Igarashi M, Saigenji K. A randomized controlled study of total parenteral nutrition and enteral nutrition by elemental and polymeric diet as primary therapy in active phase of Crohn’s disease. Nihon Shokakibyo Gakkai Zasshi. 1998;95:1212–21 (in Japanese).
108.
Jones VA. Comparison of total parenteral nutrition and elemental diet in induction of remission of Crohn’s disease. Long-term maintenance of remission by personalized food exclusion diets. Dig Dis Sci. 1987;32:100S–7S.PubMedCrossRef
109.
Fuchigami T, Ohgushi H, Imamura K, Yao T, Omae T, Watanabe H, et al. Effects of total parenteral nutrition on colonic lesions in Crohn’s disease: radiographic and endoscopic study. Gastroenterol Jpn. 1982;17:521–9.PubMed
110.
Galandiuk S, O’Neill M, McDonald P, Fazio VW, Steiger E. A century of home parenteral nutrition for Crohn’s disease. Am J Surg. 1990;159:540–4.PubMedCrossRef
111.
Fukuda Y, Matsui T, Suzuki Y, Kanke K, Matsumoto T, Takazoe M, et al. Adsorptive granulocyte and monocyte apheresis for refractory Crohn’s disease: an open multicenter prospective study. J Gastroenterol. 2004;39:1158–64.PubMedCrossRef
112.
Thirlby RC, Land JC, Fenster LF, Lonborg R. Effect of surgery on health-related quality of life in patients with inflammatory bowel disease: a prospective study. Arch Surg. 1998;133:826–32.PubMedCrossRef
113.
Homer DR, Grand RJ, Colodny AH. Growth, course, and prognosis after surgery for Crohn’s disease in children and adolescents. Pediatrics. 1977;59:717–25.PubMed
114.
Fukushima T, Sugita A. A study of factors for postoperative recurrence of Crohn’s disease. Annual reports of the research group of intractable inflammatory bowel disease subsidized by the Ministry of Health, Labour, and Welfare of Japan, Tokyo, Japan, 1995. p. 99–102 (in Japanese).
115.
Matsui T, Tsuda S, Matake H, Ikeda K, Yao T. Long-term outcome of endoscopic balloon dilation in obstructive gastrointestinal Crohn’s disease. Dig Endosc. 2004;16:S27–30.CrossRef
116.
Hassan C, Zullo A, De Francesco V, Ierardi E, Giustini M, Pitidis A, et al. Systematic review: endoscopic dilatation in Crohn’s disease. Aliment Pharmacol Ther. 2007;26:1457–64.PubMedCrossRef
117.
Anthonisen P, Barany F, Folkenborg O, Holtz A, Jarnum S, Kristensen M, et al. The clinical effect of salazosulphapyridine (Salazopyrin) in Crohn’s disease. A controlled double-blind study. Scand J Gastroenterol. 1974;9:549–54.PubMed
118.
Rijk MC, van Hogezand RA, van Lier HJ, van Tongeren JH. Sulphasalazine and prednisone compared with sulphasalazine for treating active Crohn disease. A double-blind, randomized, multicenter trial. Ann Intern Med. 1991;114:445–50.PubMed
119.
Summers RW, Switz DM, Sessions JT Jr, Becktel JM, Best WR, Kern F Jr, et al. National Cooperative Crohn’s Disease Study: results of drug treatment. Gastroenterology. 1979;77:847–69.PubMed
120.
Munakata A, Hiwatashi N, Muto T, Tsuchiya S, Fukushima T, Kobayashi J, et al. Clinical effects of N-5ASA (oral controlled -release mesalazine) on Crohn’s disease: a multicenter, open-label, dose-ranging study). Jpn Pharmacol Ther. 1994;22:S2531–54 (in Japanese).
121.
Singleton JW, Hanauer SB, Gitnick GL, Peppercorn MA, Robinson MG, Wruble LD, et al. Mesalamine capsules for the treatment of active Crohn’s disease: results of a 16-week trial. Pentasa Crohn’s Disease Study Group. Gastroenterology. 1993;104:1293–301.PubMed
122.
Prantera C, Cottone M, Pallone F, Annese V, Franze A, Cerutti R, et al. Mesalamine in the treatment of mild to moderate active Crohn’s ileitis: results of a randomized, multicenter trial. Gastroenterology. 1999;116:521–6.PubMedCrossRef
123.
Colombel JF, Lemann M, Cassagnou M, Bouhnik Y, Duclos B, Dupas JL, et al. A controlled trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn’s disease. Groupe d’Etudes Therapeutiques des Affections Inflammatoires Digestives (GETAID). Am J Gastroenterol. 1999;94:674–8.PubMedCrossRef
124.
Zoli G, Care M, Parazza M, Spano C, Biagi PL, Bernardi M, et al. A randomized controlled study comparing elemental diet and steroid treatment in Crohn’s disease. Aliment Pharmacol Ther. 1997;11:735–40.PubMedCrossRef
125.
Feagan BG, Rochon J, Fedorak RN, Irvine EJ, Wild G, Sutherland L, et al. Methotrexate for the treatment of Crohn’s disease. The North American Crohn’s Study Group Investigators. N Engl J Med. 1995;332:292–7.PubMedCrossRef
126.
Alfadhli AA, McDonald JW, Feagan BG. Methotrexate for induction of remission in refractory Crohn’s disease. Cochrane Database Syst Rev. 2005;1:CD003459.PubMed
127.
Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. Crohn’s Disease cA2 Study Group. N Engl J Med. 1997;337:1029–35.PubMedCrossRef
128.
Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet. 2002;359:1541–9.PubMedCrossRef
129.
Shaffer JA, Williams SE, Turnberg LA, Houston JB, Rowland M. Absorption of prednisolone in patients with Crohn’s disease. Gut. 1983;24:182–6.PubMedCrossRef
130.
Whiteford MH, Kilkenny J 3rd, Hyman N, Buie WD, Cohen J, Orsay C, et al. Practice parameters for the treatment of perianal abscess and fistula-in-ano (revised). Dis Colon Rectum. 2005;48:1337–42.PubMedCrossRef
131.
Sandborn W, Fazio VW, Feagan BG, Hanauer SB, Committee AGACP. American Gastroenterological Association medical position statement: perianal Crohn’s disease. Gastroenterology. 2003;125:1503–7.CrossRef
132.
Pearson DC, May GR, Fick GH, Sutherland LR. Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Intern Med. 1995;123:132–42.PubMed
133.
Strong SA, Koltun WA, Hyman NH, Buie WD. Practice parameters for the surgical management of Crohn’s disease. Dis Colon Rectum. 2007;50:1735–46.PubMedCrossRef
134.
Judge TA, Lichtenstein GR. Fistulizing Crohn’s disease. In: Sartor RB, Sandborn W, editors. Kirsner’s inflammatory bowel diseases. 6th ed. Edinburgh: Saunders; 2004. p. 700–16.
135.
Vader JP, Froehlich F, Juillerat P, Burnand B, Felley C, Gonvers JJ, et al. Appropriate treatment for Crohn’s disease: methodology and summary results of a multidisciplinary international expert panel approach—EPACT. Digestion. 2006;73:237–48.PubMedCrossRef
136.
Thomas-Gibson S, Brooker JC, Hayward CM, Shah SG, Williams CB, Saunders BP. Colonoscopic balloon dilation of Crohn’s strictures: a review of long-term outcomes. Eur J Gastroenterol Hepatol. 2003;15:485–8.PubMed
137.
Homan WP, Tang CK, Thorbjarnarson B. Acute massive hemorrhage from intestinal Crohn disease. Report of seven cases and review of the literature. Arch Surg. 1976;111:901–5.PubMedCrossRef
138.
Tsujikawa T, Nezu R, Andoh A, Saotome T, Araki Y, Ishizuka Y, et al. Infliximab as a possible treatment for the hemorrhagic type of Crohn’s disease. J Gastroenterol. 2004;39:284–7.PubMedCrossRef
139.
Robert JR, Sachar DB, Greenstein AJ. Severe gastrointestinal hemorrhage in Crohn’s disease. Ann Surg. 1991;213:207–11.PubMedCrossRef
140.
Belaiche J, Louis E, D’Haens G, Cabooter M, Naegels S, De Vos M, et al. Acute lower gastrointestinal bleeding in Crohn’s disease: characteristics of a unique series of 34 patients. Belgian IBD Research Group. Am J Gastroenterol. 1999;94:2177–81.PubMedCrossRef
141.
Yamaguchi A, Matsui T, Sakurai T, Ueki T, Nakabayashi S, Yao T, et al. The clinical characteristics and outcome of intraabdominal abscess in Crohn’s disease. J Gastroenterol. 2004;39:441–8.PubMedCrossRef
142.
Potthast S, Rieber A, Von Tirpitz C, Wruk D, Adler G, Brambs HJ. Ultrasound and magnetic resonance imaging in Crohn’s disease: a comparison. Eur Radiol. 2002;12:1416–22.PubMedCrossRef
143.
Gervais DA, Hahn PF, O’Neill MJ, Mueller PR. Percutaneous abscess drainage in Crohn disease: technical success and short- and long-term outcomes during 14 years. Radiology. 2002;222:645–51.PubMedCrossRef
144.
Gutierrez A, Lee H, Sands BE. Outcome of surgical versus percutaneous drainage of abdominal and pelvic abscesses in Crohn’s disease. Am J Gastroenterol. 2006;101:2283–9.PubMedCrossRef
145.
Van den Bosch F, Kruithof E, De Vos M, De Keyser F, Mielants H. Crohn’s disease associated with spondyloarthropathy: effect of TNF-alpha blockade with infliximab on articular symptoms. Lancet. 2000;356:1821–2.PubMedCrossRef
146.
Brooklyn TN, Dunnill MG, Shetty A, Bowden JJ, Williams JD, Griffiths CE, et al. Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Gut. 2006;55:505–9.PubMedCrossRef
147.
Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet. 2002;359:1187–93.PubMedCrossRef
148.
Sutherland LR, Ramcharan S, Bryant H, Fick G. Effect of cigarette smoking on recurrence of Crohn’s disease. Gastroenterology. 1990;98:1123–8.PubMed
149.
Mawdsley JE, Rampton DS. Psychological stress in IBD: new insights into pathogenic and therapeutic implications. Gut. 2005;54:1481–91.PubMedCrossRef
150.
Cosnes J, Cattan S, Blain A, Beaugerie L, Carbonnel F, Parc R, et al. Long-term evolution of disease behavior of Crohn’s disease. Inflamm Bowel Dis. 2002;8:244–50.PubMedCrossRef
151.
Akobeng AK. The evidence base for interventions used to maintain remission in Crohn’s disease. Aliment Pharmacol Ther. 2008;27:11–8.PubMedCrossRef
152.
Rutgeerts P, D’Haens G, Targan S, Vasiliauskas E, Hanauer SB, Present DH, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn’s disease. Gastroenterology. 1999;117:761–9.PubMedCrossRef
153.
Camma C, Giunta M, Rosselli M, Cottone M. Mesalamine in the maintenance treatment of Crohn’s disease: a meta-analysis adjusted for confounding variables. Gastroenterology. 1997;113:1465–73.PubMedCrossRef
154.
Lemann M, Mary JY, Colombel JF, Duclos B, Soule JC, Lerebours E, et al. A randomized, double-blind, controlled withdrawal trial in Crohn’s disease patients in long-term remission on azathioprine. Gastroenterology. 2005;128:1812–8.PubMedCrossRef
155.
Yamamoto T, Nakahigashi M, Saniabadi AR, Iwata T, Maruyama Y, Umegae S, et al. Impacts of long-term enteral nutrition on clinical and endoscopic disease activities and mucosal cytokines during remission in patients with Crohn’s disease: a prospective study. Inflamm Bowel Dis. 2007;13:1493–501.PubMedCrossRef
156.
Verma S, Kirkwood B, Brown S, Giaffer MH. Oral nutritional supplementation is effective in the maintenance of remission in Crohn’s disease. Dig Liver Dis. 2000;32:769–74.PubMedCrossRef
157.
Jutta K, Heidi P, Peter L. Management of the short bowel syndrome after extensive small bowel resection. Best Pract Res Clin Gastroenterol. 2004;18:977–92.
158.
Yao T, Sakurai T, Hiwatashi N. A study of long-term prognosis of Crohn’s disease -cumulative mortality and cumulative rate of surgery. Annual reports of the research group of intractable inflammatory bowel disease subsidized by the Ministry of Health, Labour, and Welfare of Japan, Tokyo, Japan, 1992. p. 49–51 (in Japanese).
159.
Cantor M, Bernstein CN. Clinical course and natural history of ulcerative colitis. In: Sartor RB, Sandborn W, editors. Kirsner’s inflammatory bowel diseases. Edinburgh: Saunders; 2004. p. 280–88.
160.
Sugita A, Kimura H, Koganei K, Ohtsuki K, Futatsuki R, Fukushima T, et al. Surgical treatment for gastroduodenal Crohn’s disease. Stomach Intestine. 2007;42:477–84 (in Japanese).
161.
Ulman TA, Itzkowitx SH. Cancer risk in inflammatory bowel disease. In: Satsangi J, Sutherland LR, editors. Inflammatory bowel disease. Philadelphia: Churchill Livingstone; 2003. p. 605–19.
162.
Fazio VW, Marchetti F, Church M, Goldblum JR, Lavery C, Hull TL, et al. Effect of resection margins on the recurrence of Crohn’s disease in the small bowel. A randomized controlled trial. Ann Surg. 1996;224:563–71 (discussion 571–3).
163.
Post S, Herfarth C, Bohm E, Timmermanns G, Schumacher H, Schurmann G, et al. The impact of disease pattern, surgical management, and individual surgeons on the risk for relaparotomy for recurrent Crohn’s disease. Ann Surg. 1996;223:253–60.PubMedCrossRef
164.
Ozuner G, Fazio VW, Lavery IC, Milsom JW, Strong SA. Reoperative rates for Crohn’s disease following strictureplasty. Long-term analysis. Dis Colon Rectum. 1996;39:1199–203.PubMedCrossRef
165.
Sasaki I, Funayama Y, Naito H, Fukushima K, Shibata C, Matsuno S. Extended strictureplasty for multiple short skipped strictures of Crohn’s disease. Dis Colon Rectum. 1996;39:342–4.PubMedCrossRef
166.
Michelassi F. Side-to-side isoperistaltic strictureplasty for multiple Crohn’s strictures. Dis Colon Rectum. 1996;39:345–9.PubMedCrossRef
167.
Hughes LE, Taylor BA. Perianal lesions in Crohn’s disease. In: Allan RN, Keighley MR, Alexander-Williams J, Hawkins C, editors. Inflammatory bowel disease. Philadelphia: Churchill Livingstone; 1990. p. 351–61.
168.
Sugita A. Features and prognosis of small/colorectal cancer complicated with ulerative colitis/Crohn’s disease. Annual reports of the research group of intractable inflammatory bowel disease subsidized by the Ministry of Health, Labour, and Welfare of Japan, Tokyo, Japan, 2008. p. 87–9 (in Japanese).
169.
Kogenei K, Kimura H, Arai K, Sugita A, Fukushima T. Efficacy and problems of fecal diversion for intractable anorectal complications of Crohn’s disease. Jpn J Gastroenterol Surg. 2005;38:1543–48 (in Japanese).
170.
Post S, Herfarth C, Schumacher H, Golling M, Schurmann G, Timmermanns G. Experience with ileostomy and colostomy in Crohn’s disease. Br J Surg. 1995;82:1629–33.PubMedCrossRef
171.
Rutgeerts P, Geboes K, Vantrappen G, Kerremans R, Coenegrachts JL, Coremans G. Natural history of recurrent Crohn’s disease at the ileocolonic anastomosis after curative surgery. Gut. 1984;25:665–72.PubMedCrossRef
172.
Williams JG, Wong WD, Rothenberger DA, Goldberg SM. Recurrence of Crohn’s disease after resection. Br J Surg. 1991;78:10–9.PubMedCrossRef
173.
Fukushima K, Sugita A, Baba S. A study of factors for postoperative recurrence of Crohn’s disease. Annual reports of the research group of intractable inflammatory bowel disease subsidized by the Ministry of Health, Labour, and Welfare of Japan, Tokyo, Japan, 1996. p. 58–60 (in Japanese).
174.
Raab Y, Bergstrom R, Ejerblad S, Graf W, Pahlman L. Factors influencing recurrence in Crohn’s disease. An analysis of a consecutive series of 353 patients treated with primary surgery. Dis Colon Rectum. 1996;39:918–25.PubMedCrossRef
175.
Greenstein AJ, Lachman P, Sachar DB, Springhorn J, Heimann T, Janowitz HD, et al. Perforating and non-perforating indications for repeated operations in Crohn’s disease: evidence for two clinical forms. Gut. 1988;29:588–92.PubMedCrossRef
176.
Simillis C, Yamamoto T, Reese GE, Umegae S, Matsumoto K, Darzi AW, et al. A meta-analysis comparing incidence of recurrence and indication for reoperation after surgery for perforating versus nonperforating Crohn’s disease. Am J Gastroenterol. 2008;103:196–205.PubMedCrossRef
177.
McLeod RS, Wolff BG, Steinhart AH, Carryer PW, O’Rourke K, Andrews DF, et al. Prophylactic mesalamine treatment decreases postoperative recurrence of Crohn’s disease. Gastroenterology. 1995;109:404–13.PubMedCrossRef
178.
Rutgeerts P, Hiele M, Geboes K, Peeters M, Penninckx F, Aerts R, et al. Controlled trial of metronidazole treatment for prevention of Crohn’s recurrence after ileal resection. Gastroenterology. 1995;108:1617–21.PubMedCrossRef
179.
Hanauer SB, Korelitz BI, Rutgeerts P, Peppercorn MA, Thisted RA, Cohen RD, et al. Postoperative maintenance of Crohn’s disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial. Gastroenterology. 2004;127:723–9.PubMedCrossRef
180.
Matsui T, Seki T, Yao K, Sou S, Hirai F. Diagnosis of inflammatory diseases of the small intestine: comparison between double balloon enteroscopy and double contrast radiography. Stomach Intestine. 2005;40:1491–502 (in Japanese).
181.
Consigny Y, Modigliani R, Colombel JF, Dupas JL, Lemann M, Mary JY. A simple biological score for predicting low risk of short-term relapse in Crohn’s disease. Inflamm Bowel Dis. 2006;12:551–7.PubMedCrossRef
182.
Canavan C, Abrams KR, Mayberry J. Meta-analysis: colorectal and small bowel cancer risk in patients with Crohn’s disease. Aliment Pharmacol Ther. 2006;23:1097–104.PubMedCrossRef
183.
Jess T, Riis L, Vind I, Winther KV, Borg S, Binder V, et al. Changes in clinical characteristics, course, and prognosis of inflammatory bowel disease during the last 5 decades: a population-based study from Copenhagen, Denmark. Inflamm Bowel Dis. 2007;13:481–9.PubMedCrossRef
184.
Masunaga Y, Ohno K, Ogawa R, Hashiguchi M, Echizen H, Ogata H. Meta-analysis of risk of malignancy with immunosuppressive drugs in inflammatory bowel disease. Ann Pharmacother. 2007;41:21–8.PubMedCrossRef
185.
Rosh JR, Gross T, Mamula P, Griffiths A, Hyams J. Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn’s disease: a cautionary tale? Inflamm Bowel Dis. 2007;13:1024–30.PubMedCrossRef
186.
Friedman S, Rubin PH, Bodian C, Goldstein E, Harpaz N, Present DH. Screening and surveillance colonoscopy in chronic Crohn’s colitis. Gastroenterology. 2001;120:820–6.PubMedCrossRef
187.
Geborek P, Bladstrom A, Turesson C, Gulfe A, Petersson IF, Saxne T, et al. Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis. 2005;64:699–703.PubMedCrossRef
188.
Wolfe F, Michaud K. The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation. Arthritis Rheum. 2007;56:1433–9.PubMedCrossRef
189.
Oriuchi T, Hiwatashi N, Katsurashima Y, Noguchi M, Kinouchi Y, Toyota T. Inflammatory bowel disease and pregnancy: clinical study of mutual influence, clinical course and treatment. Nihon Shokakibyo Gakkai Zasshi. 1999;96:266–72 (in Japanese).
190.
Mayberry JF, Weterman IT. European survey of fertility and pregnancy in women with Crohn’s disease: a case control study by European collaborative group. Gut. 1986;27:821–5.PubMedCrossRef
191.
Moody GA, Probert C, Jayanthi V, Mayberry JF. The effects of chronic ill health and treatment with sulphasalazine on fertility amongst men and women with inflammatory bowel disease in Leicestershire. Int J Colorectal Dis. 1997;12:220–4.PubMedCrossRef
192.
Narendranathan M, Sandler RS, Suchindran CM, Savitz DA. Male infertility in inflammatory bowel disease. J Clin Gastroenterol. 1989;11:403–6.PubMedCrossRef
193.
Moody GA, Mayberry JF. Perceived sexual dysfunction amongst patients with inflammatory bowel disease. Digestion. 1993;54:256–60.PubMedCrossRef
194.
Norgard B, Pedersen L, Christensen LA, Sorensen HT. Therapeutic drug use in women with Crohn’s disease and birth outcomes: a Danish nationwide cohort study. Am J Gastroenterol. 2007;102:1406–13.PubMedCrossRef
195.
Bortoli A, Saibeni S, Tatarella M, Prada A, Beretta L, Rivolta R, et al. Pregnancy before and after the diagnosis of inflammatory bowel diseases: retrospective case–control study. J Gastroenterol Hepatol. 2007;22:542–9.PubMedCrossRef
196.
Dominitz JA, Young JC, Boyko EJ. Outcomes of infants born to mothers with inflammatory bowel disease: a population-based cohort study. Am J Gastroenterol. 2002;97:641–8.PubMedCrossRef
197.
Baird DD, Narendranathan M, Sandler RS. Increased risk of preterm birth for women with inflammatory bowel disease. Gastroenterology. 1990;99:987–94.PubMed
198.
Francella A, Dyan A, Bodian C, Rubin P, Chapman M, Present DH. The safety of 6-mercaptopurine for childbearing patients with inflammatory bowel disease: a retrospective cohort study. Gastroenterology. 2003;124:9–17.PubMedCrossRef
199.
Caprilli R, Gassull MA, Escher JC, Moser G, Munkholm P, Forbes A, et al. European evidence based consensus on the diagnosis and management of Crohn’s disease: special situations. Gut. 2006;55:i36–58.PubMedCrossRef
200.
Mahadevan U, Kane S, Sandborn WJ, Cohen RD, Hanson K, Terdiman JP, et al. Intentional infliximab use during pregnancy for induction or maintenance of remission in Crohn’s disease. Aliment Pharmacol Ther. 2005;21:733–8.PubMedCrossRef
201.
Katz JA, Antoni C, Keenan GF, Smith DE, Jacobs SJ, Lichtenstein GR. Outcome of pregnancy in women receiving infliximab for the treatment of Crohn’s disease and rheumatoid arthritis. Am J Gastroenterol. 2004;99:2385–92.PubMedCrossRef
202.
Present DH. Pregnancy and inflammatory bowel disease. In: Bayless TM, Hanauer SB, editors. Advanced therapy of inflammatory bowel disease. Shelton: PMPH-USA; 2001. p. 613–8.
203.
Kinjo F, Chinen H. Issues of pregnancy and delivery in IBD. IBD Res. 2008;2:61–6 (in Japanese).
204.
Miller LG, Hopkinson JM, Motil KJ, Corboy JE, Andersson S. Disposition of olsalazine and metabolites in breast milk. J Clin Pharmacol. 1993;33:703–6.PubMed
205.
Esbjorner E, Jarnerot G, Wranne L. Sulphasalazine and sulphapyridine serum levels in children to mothers treated with sulphasalazine during pregnancy and lactation. Acta Paediatr Scand. 1987;76:137–42.PubMedCrossRef
Metadata
Title
Evidence-based clinical practice guidelines for Crohn’s disease, integrated with formal consensus of experts in Japan
Authors
Fumiaki Ueno
Toshiyuki Matsui
Takayuki Matsumoto
Katsuyoshi Matsuoka
Mamoru Watanabe
Toshifumi Hibi
On Behalf of the Guidelines Project Group of the Research Group of Intractable Inflammatory Bowel Disease subsidized by the Ministry of Health, Labour and Welfare of Japan and the Guidelines Committee of the Japanese Society of Gastroenterology
Publication date
01-01-2013
Publisher
Springer Japan
Published in
Journal of Gastroenterology / Issue 1/2013
Print ISSN: 0944-1174
Electronic ISSN: 1435-5922
DOI
https://doi.org/10.1007/s00535-012-0673-1

Other articles of this Issue 1/2013

Journal of Gastroenterology 1/2013 Go to the issue

Review

Host factors determining the efficacy of hepatitis C treatment

Original Article—Alimentary Tract

MicroRNA-146a negatively regulates PTGS2 expression induced by Helicobacter pylori in human gastric epithelial cells

Original Article—Liver, Pancreas, and Biliary Tract

Expression of gremlin 1 correlates with increased angiogenesis and progression-free survival in patients with pancreatic neuroendocrine tumors

Original Article—Liver, Pancreas, and Biliary Tract

IL-23R polymorphisms, HBV infection, and risk of hepatocellular carcinoma in a high-risk Chinese population

Original Article—Alimentary Tract

Genetic polymorphisms of SCN10A are associated with functional dyspepsia in Japanese subjects

Original Article—Liver, Pancreas, and Biliary Tract

Loss of heterozygosity and methylation of multiple tumor suppressor genes on chromosome 3 in hepatocellular carcinoma

ACC 2024 Congress Coverage

Cardiology Video

Highlights from the ACC 2024 Congress

Watch now

Watch official videos from the ACC congress summarizing key highlights from the last year in heart failure, cardiomyopathies, valvular disease, pulmonary vascular disease, and pediatric cardiology.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits